Render Target: STATIC
Render Timestamp: 2024-12-26T10:43:22.825Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-12-03 23:01:07.543
Product last modified at: 2024-12-10T09:00:37.954Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Prostein/SLC45A3 (F5U4V) Rabbit mAb #52520

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 50
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:200

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Prostein/SLC45A3 (F5U4V) Rabbit mAb recognizes endogenous levels of total Prostein/SLC45A3 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human Prostein/SLC45A3 protein.

    Background

    Solute carrier family 45 member 3 (SLC45A3), also known as prostate cancer-associated protein 6 (prostein), is an androgen-sensitive, multi-pass transmembrane sucrose transporter (1). SLC45A3 is highly expressed in both normal prostate and prostate cancers (1). SLC45A3 may have limited expression in white matter oligodendrocytes and epithelial cells of the kidney medullary collecting duct, where it regulates oligodendrocyte differentiation and urine osmolarity, respectively (2,3). In high-grade prostate cancers, there is a loss of SLC45A3 expression that corresponds with an increase in SLC45A3 5' protein fusions with multiple ETS-family proteins, including ERG fusions (4,5), PEA3-family (ETV1, ETV4, and ETV5) fusions (6), and ELK4 fusions (7). In ETS-negative prostate cancers, SLC45A3-BRAF fusions have been observed that are sensitive to RAF inhibitors (8).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.